USA - NASDAQ:PAVM - US70387R4039 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to PAVM. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-06-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-12-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2024-09-10 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2023-08-18 | Cantor Fitzgerald | Reiterate | Neutral -> Neutral |
| 2023-01-20 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-01-18 | Lake Street | Maintains | Buy |
| 2022-08-17 | Lake Street | Maintains | Buy |
| 2021-03-30 | Cantor Fitzgerald | Initiate | Overweight |
8 analysts have analysed PAVM and the average price target is 12.24 USD. This implies a price increase of 3677.78% is expected in the next year compared to the current price of 0.324.
The consensus rating for PAVMED INC (PAVM) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering PAVMED INC (PAVM) is 8.